Table 1.
Baseline characteristics of the study population
| Study groups
|
Metformin + OA
|
Metformin + vildagliptin
|
Total
|
P-value |
|---|---|---|---|---|
| Patients, n (%) | n=717 | n=270 | n=987 | |
| Sociodemographics | ||||
| Mean age, years | 74.4 (6.2) | 73.6 (6.1) | 74.2 (6.2) | 0.077 |
| Sex (male) | 50.5% | 45.6% | 49.1% | 0.167 |
| General comorbidity | ||||
| Mean diagnoses | 5.8 (2.5) | 5.7 (2.3) | 5.8 (2.5) | 0.488 |
| Mean Charlson comorbidity index | 1 (0.4) | 1.1 (0.5) | 1.1 (0.4) | 0.296 |
| Mean RUB | 3 (0.6) | 3 (0.5) | 3 (0.6) | 0.574 |
| RUB-1 | 0.7% | 0.1% | 0.5% | |
| RUB-2 | 12.2% | 10.1% | 11.6% | |
| RUB-3 | 73.1% | 81.4% | 75.4% | |
| RUB-4 | 12.4% | 7.2% | 11.0% | |
| RUB-5 | 1.6% | 1.2% | 1.5% | 0.066 |
| Comorbidities | ||||
| Hypertension | 76.3% | 73.7% | 75.6% | 0.399 |
| Dyslipidemia | 61.2% | 63.3% | 61.8% | 0.544 |
| Obesity | 23.2% | 23.3% | 23.2% | 0.952 |
| Active smoker | 14.2% | 15.2% | 14.5% | 0.703 |
| Alcoholism | 2.5% | 2.6% | 2.5% | 0.942 |
| Ischemic heart disease | 16.3% | 14.8% | 15.9% | 0.565 |
| Cerebrovascular accident | 19.8% | 18.9% | 19.6% | 0.746 |
| Cardiovascular event | 31.2% | 28.1% | 30.4% | 0.346 |
| Organ failure | 20.2% | 21.9% | 20.7% | 0.573 |
| Bronchial asthma | 5.6% | 3.3% | 5.0% | 0.148 |
| COPD | 7.7% | 10.0% | 8.3% | 0.237 |
| Neuropathies | 1.5% | 0.4% | 1.2% | 0.137 |
| Dementia (all types) | 5.2% | 4.8% | 5.1% | 0.825 |
| Depressive syndrome | 18.8% | 22.6% | 19.9% | 0.186 |
| Malignant neoplasm | 13.5% | 11.9% | 13.1% | 0.486 |
| Relationship with diabetes | ||||
| Time since diagnosis, years | 17.4 (7.3) | 20 (5.2) | 18.1 (6.9) | 0.002 |
| Diabetic retinopathy | 28.2% | 32.0% | 29.0% | 0.346 |
| Diabetic neuropathy | 13.5% | 13.7% | 13.5% | 0.870 |
| Diabetic nephropathy | 12.1% | 12.2% | 12.1% | 0.899 |
| Change in glomerular filtration | 26.0% | 25.6% | 25.9% | 0.853 |
Note: Values expressed as the percentage or mean (standard deviation).
Abbreviations: RUB, resource utilization band; COPD, chronic obstructive pulmonary disease; OA, oral antidiabetics, including sulfonylureas and glitazones.